ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib induces a conformational change in the BCR-ABL protein and has been known as a Food and Drug Administration (FDA)-approved agent for adults with CML in the chronic phase (CP) [18,19,20].